TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer

In treating patients with castration resistant prostate cancer (CRPC), enzalutamide, the second-generation androgen receptor (AR) antagonist, is an accepted standard of care. However, clinical benefits are limited to a median time of 4.8 months because resistance inevitably emerges. To determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Geun Taek, Rosenfeld, Jeffrey A., Kim, Won Tae, Kwon, Young Suk, Palapattu, Ganesh, Mehra, Rohit, Kim, Wun-Jae, Kim, Isaac Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752758/
https://www.ncbi.nlm.nih.gov/pubmed/31536510
http://dx.doi.org/10.1371/journal.pone.0213488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752758/
https://www.ncbi.nlm.nih.gov/pubmed/31536510
http://dx.doi.org/10.1371/journal.pone.0213488

Ejemplares similares